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OBJECTIVES To predict which patients might not require stent implantation, we identified clinical and
angiographic characteristics associated with repeat revascularization after standard balloon
angioplasty.
BACKGROUND Stents reduce the risk of repeat revascularization but are costly and may lead to in-stent
restenosis, which remains difficult to treat. Identification of patients at low risk for repeat
revascularization may allow clinicians to reserve stents for patients most likely to benefit.
METHODS Data from five interventional trials (5,146 patients) were pooled for analysis. We identified
patients with optimal angiographic results (final diameter stenosis #30% and no dissection)
after balloon angioplasty and determined the multivariable predictors of repeat revascular-
ization.
RESULTS Optimal angiographic results were achieved in 18% of patients after angioplasty. The repeat
revascularization rate at six months was lower for patients with optimal results (20% vs. 26%,
p , 0.001) but still higher than observed in stent trials. Independent predictors of repeat
revascularization were female gender (odds ratio [OR] 1.67, p 5 0.01), lesion length $10 mm
(OR 1.62, p 5 0.03) and proximal left anterior descending coronary artery lesions (OR 1.62,
p 5 0.03). For the 8% of patients with optimal angiographic results and none of these risk
factors, the repeat revascularization and target vessel revascularization rates were 14% and 8%
respectively, similar to rates after stent implantation. Cost analysis estimated that $78 million
per year might be saved in the U.S. with a provisional stenting strategy using these criteria
compared with elective stenting.
CONCLUSIONS A combination of baseline characteristics and angiographic results can be used to identify a
small group of patients at very low risk for repeat revascularization after balloon angioplasty.
Provisional stenting for these low risk patients could substantially reduce costs without
compromising clinical outcomes. (J Am Coll Cardiol 2001;37:1883–90) © 2001 by the
American College of Cardiology
Coronary stents have been shown to reduce rates of clinical
and angiographic restenosis in selected patients (1,2). Stent
implantation is costly, however, adding more than $2,000 in
direct costs to each interventional case (3). Given these cost
considerations, provisional stenting (stenting in selective
cases as opposed to all cases) has been proposed as an
alternative (4). The selection criteria for provisional stent-
ing, however, have not been fully elucidated.
We hypothesized that the same low rate of repeat
revascularization might be achieved without stent implan-
tation when optimal angiographic results are obtained from
balloon angioplasty alone. Specifically, using a large registry
from five clinical trials, we investigated the degree to which
angiographic results, patient clinical characteristics or both
could be used to identify patients with low repeat revascu-
larization rates. After defining these angiographic and
clinical criteria, we determined the potential economic
effects of applying these criteria to limit elective stent usage.
METHODS
Patient population. Data were pooled from five random-
ized trials of percutaneous coronary interventions (5–9).
The protocols and study populations of the five trials and
the methods used to pool the data have been described in
detail (10). The Coronary Angioplasty Versus Excisional
Atherectomy Trial (CAVEAT) randomized 1,012 patients
to undergo angioplasty or directional coronary atherectomy.
Patients who underwent atherectomy were excluded from
the analysis. In both the Evaluation of 7E3 for the Preven-
tion of Ischemic Complications (EPIC) (2,099 patients)
and Integrilin to Minimize Platelet Aggregation and Cor-
onary Thrombosis (IMPACT-II) (4,010 patients) studies,
patients undergoing percutaneous interventions were ran-
domly allocated to receive placebo or an intravenous glyco-
protein IIb/IIIa inhibitor—abciximab or eptifibatide, re-
spectively. The Multicenter American Research trial with
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Cilazapril after Angioplasty To prevent coronary Obstruc-
tion and Restenosis (MARCATOR) assessed the effect of
cilazapril on restenosis in 1,436 patients undergoing angio-
plasty. The Perfusion Balloon Catheter (PBC) study com-
pared prolonged versus short inflations using the perfusion-
balloon catheter in 478 patients.
The data in these trials were collected during various
periods, ranging from April 1989 to November 1995.
Patients with acute myocardial infarction (MI) were ex-
cluded before pooling the data. The pooled data contain
detailed clinical and angiographic data for 8,726 patients.
After excluding patients who had stents implanted (n 5
159), vein-graft intervention (n 5 322), left-main interven-
tion (n 5 130), atherectomy or laser treatment (n 5 1,469),
failed or partially successful angioplasty (final diameter
stenosis $50% in any attempted lesion, n 5 1,047) and
incomplete angiographic data or six-month status (n 5
453), there were 5,146 patients for this analysis.
Interventional procedures. Before the procedure, all pa-
tients received aspirin (160 to 325 mg/day). Patients in the
PBC trial also received dipyridamole. Angioplasty proce-
dures were performed using standard techniques, with the
exception of perfusion-balloon catheters used in the PBC
trial. Stenting was unusual in these trials (and excluded from
this analysis), being performed in ,2% of cases. Intravenous
glycoprotein IIb/IIIa inhibitors were used only in the active
treatment arms of EPIC and IMPACT-II, accounting for
2,099 (41%) of the patients in this analysis. During the
procedure, all patients received intravenous heparin to reach
a target activated clotting time of .300 s (.350 s for
CAVEAT). After intervention, creatine kinase (CK)-MB
levels were obtained routinely over the next 24 h. All
patients were discharged on aspirin 325 mg/day.
Data collection. For each trial, the participating sites
collected data prospectively on case report forms and sent
them to data coordinating centers. Verification of the data
was performed using consistency checks and double data
entry. Sites were queried for missing or questionable data.
The dataset for each trial was verified by retrospective
review of patient charts. Complete copies of the individual
datasets from the five trials were combined into a single
database.
Clinical follow-up. All five trials followed patients for at
least six months for the occurrence of death, MI, repeat
angioplasty or bypass surgery. For repeat angioplasty, in-
volvement of the target vessel was not recorded in
MARCATOR but was specified in the other trials.
Angiographic analysis. For all five trials, cineangiograms
were sent for review to independent core angiographic
laboratories blind to treatment assignment. For EPIC and
IMPACT-II, diameter stenosis was measured using calipers
without catheter calibration. Except for 860 patients in the
IMPACT-II angiographic substudy, absolute lumen di-
mensions were not obtained for patients in these two trials.
For the other three trials and for the IMPACT-II angio-
graphic substudy, quantitative coronary angiography (QCA)
was performed using automated edge-detection algorithms
as described previously (11,12).
Definitions. Myocardial infarction was defined as new
Q-waves on the electrocardiogram or elevation of CK or
CK-MB. Enzymatic criteria for MI were values $2 times
the upper limit of normal for MARCATOR and the PBC
trial and three times the upper limit for the other trials. All
events were adjudicated by independent committees blind to
randomization. Repeat revascularization included all repeat
percutaneous coronary interventions and bypass operations
within the first six months, whether or not the target lesion
was involved. To estimate the rate of target vessel revascu-
larization (TVR), repeat percutaneous interventions without
target vessel data were assumed to have the same proportion
of target vessel involvement as the population for whom
these data were available. All surgical procedures were
assumed to have involved the target vessel. Multilesion
interventions were considered “stent-like” results only if the
stent-like criteria were achieved in all lesions attempted.
Statistical analysis. Baseline, procedural and angiographic
characteristics are summarized as medians with 25th and
75th percentiles for continuous measures and as percentages
for discrete measures. Event rates are summarized as per-
centages with 95% CI. For comparisons between groups,
the likelihood ratio chi-square test was used for discrete
variables and the Wilcoxon rank-sum test was used for
continuous variables. Sensitivity and specificity for predict-
ing six-month survival free of repeat revascularization were
calculated for stent-like result (SLR) criteria based on
absence of dissection and residual diameter stenosis levels of
#10%, #20%, #25%, #30%, #40% and #50%. These
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criteria excluded all dissections, on the basis of a survey that
indicates that most interventional cardiologists use stents
routinely for any angiographically visible dissection (Cantor
et al., unpublished data). We defined the best threshold for
residual diameter stenosis to be the level that included the
most patients yet maintained $80% specificity to predict
survival free of repeat revascularization at six months.
Multivariable logistic regression was performed using a
stepwise, backward-elimination algorithm to determine in-
dependent predictors of repeat revascularization at six
months in cases with SLRs. Variables were included in the
multivariable model if they were significant in univariable
analysis or if considered clinically important. The indepen-
dent predictors were used to construct a classification and
regression tree and classify patients with stent-like angio-
graphic results as high or low risk for repeat revasculariza-
tion. We validated the CART model by dividing the data
into training and test sets to do the development and testing
separately. We developed the classification scheme on half
of the patients with SLR and tested it on the other half.
Once agreement between the two samples was established,
we then applied the scheme to the full sample using SLR as
the first split in the tree.
Cost-effectiveness analysis. The six-month costs and clin-
ical outcomes of elective and provisional stenting strategies
were compared using decision-analysis techniques (DATA
3.5, Treeage Software, Williamstown, Massachusetts). The
rates of stenting for the provisional stent strategies and the
probability of repeat revascularization after balloon angio-
plasty were based on the results of the analysis described in
the preceding text. The cost estimates for angioplasty, stent
procedures and bypass surgery were based on a cost analysis
of patients undergoing percutaneous coronary intervention
at Duke University Medical Center (3). This previous
analysis was based on the Transition 1 Accounting System
(Transition Systems, Inc., Boston, Massachusetts), which
contains detailed cost records at the intermediate product
level within each department (for example, number of
specific diagnostic tests, hours of care by in-patient unit or
time spent in catheterization laboratory). The acquisition
cost of a stent was $1,595. For this analysis, indirect costs
associated with stent and angioplasty procedures were as-
sumed to be equal. The repeat revascularization rate for
stented patients was estimated from randomized trial and
registry results (2,13,14). Sensitivity analysis was performed
to examine the effects of varying estimated costs and event
rates over a wide range of values.
RESULTS
Determination of angiographic diameter stenosis criteria
for SLR. A total of 5,146 patients were included in the
analysis. The numbers of patients with final diameter
stenoses at or below various thresholds are summarized in
Table 1. Only 1% of cases achieved a residual diameter
stenosis #10% with no dissection as assessed by the core
lab. The event rates for the composite end point of death,
MI or any repeat revascularization for the different criteria
of SLR are shown in Figure 1. Although there was no
apparent relation between the final diameter stenosis and
Figure 1. Clinical event rates at six months for four different thresholds of postintervention diameter stenosis. DS 5 diameter stenosis; MI 5 myocardial
infarction; QCA 5 quantitative coronary angiography.
Table 1. Freedom From Repeat Revascularization at
Six Months
Final Diameter
Stenosis* n (%) Sensitivity Specificity
#10% 64 (1.2%) 1.4% 99.2%
#20% 319 (6.2%) 6.7% 95.5%
#25% 575 (11.2%) 11.9% 90.9%
#30% 938 (18.2%) 19.3% 85.1%
#35% 1,351 (26.3%) 27.3% 76.9%
#40% 1,793 (34.8%) 35.4% 67.0%
#50% 2,329 (45.3%) 61.2% 55.7%
*With no angiographically visible dissection.
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the rates of death and MI, the repeat revascularization rates
increased with increasing diameter stenosis thresholds. The
sensitivity and specificity for the different thresholds of
postangioplasty residual diameter stenosis (core laboratory
determination) in predicting freedom from repeat revascu-
larization are shown in Table 1. To maintain $80%
specificity, a diameter stenosis threshold #30% would need
to be used as criteria for a SLR. The clinical event rates for
the final diameter stenosis thresholds of 20%, 25% and 30%
were similar. Therefore, we defined a SLR as a final
diameter stenosis #30% without dissection. Only 938
eligible patients (18%) met these criteria.
Clinical outcomes with SLRs. The six-month rates of
death, MI and repeat revascularization for the two groups
are summarized in Table 2. Patients with SLR had signif-
icantly lower rates of MI (4% vs. 6%; p 5 0.009) and repeat
revascularization (20% vs. 26%; p , 0.001). In the SLR
group, the target vessel was involved in 64 (65%) of the
repeat angioplasty cases in which vessel location was known.
The estimated TVR rate for the SLR group was 14.5%.
Predictors of repeat revascularization. Univariate and
multivariable regression analyses were performed for the
SLR cases to identify predictors of repeat revascularization
at six months (Table 3). The univariate predictors of repeat
revascularization were female gender, proximal left anterior
descending coronary artery (LAD) lesion, lesion length
$10 mm and no prior MI. The same four variables were
independent predictors of repeat revascularization in the
multivariate model.
Subgroups of the SLRs. Figure 2 shows the classification
and regression tree analysis for patients who achieved
stent-like angiographic results, stratified by presence or
absence of three of the independent predictors of repeat
revascularization. In the lowest risk subgroup (men with
lesions ,10 mm long and no proximal LAD lesions) the
repeat revascularization rate at six months was 14% (95%
CI, 10% to 18%). The estimated TVR rate in this group was
8.1%. In contrast, the repeat revascularization rate of the
highest risk subgroup (women with lesions $10 mm long
and proximal LAD lesions) was 46% (95% CI, 20% to
68%). About 45% of patients with an SLR (excluding cases
for which lesion length was missing) were in the lowest risk
subgroup, representing about 8% of all eligible patients.
Economic implications of the two provisional stenting
strategies. We evaluated the expected repeat revasculariza-
tion rates and costs of two provisional stenting strategies
and an elective stenting strategy for stent use based on event
rates described in the preceding text. In the elective stenting
strategy, all patients would undergo stent implantation
irrespective of the angiographic result after balloon angio-
Table 2. Six-Month Clinical Outcomes With and Without Stent-Like Results
Stent-Like
Result (n 5 938)
No Stent-Like Result
(n 5 4,208) p Value
Death 0.4% (0.0–0.9) 0.6% (0.3–0.8) 0.6
Myocardial infarction 3.6% (2.4–4.8) 5.6% (4.9–6.3) 0.009
Repeat angioplasty 17.1% (14.7–19.5) 21.0% (19.7–22.2) 0.007
Bypass surgery 4.4% (3.1–5.8) 6.6% (5.8–7.3) 0.11
Any repeat revascularization 20.0% (17.5–22.6) 25.5% (24.1–26.8) , 0.001
Composite of above 22.0% (19.3–24.6) 27.6% (26.3–29.0) , 0.001
Data are presented as percentage (95% CI).
Table 3. Predictors of Repeat Revascularization at Six Months
Factor
Univariable Multivariable
Odds Ratio
(95% CI)
p
Value
Odds Ratio
(95% CI)
p
Value
Age (per 10-year increase) 1.12 (0.97–1.30) 0.13
Female gender 1.88 (1.34–2.64) , 0.001 1.67 (1.12–2.48) 0.01
Diabetes 1.14 (0.77–1.69) 0.50
Congestive heart failure 0.63 (0.26–1.53) 0.31
Unstable angina 1.16 (0.80–1.66) 0.44
Prior infarction 0.71 (0.52–0.99) 0.04 0.68 (0.46–1.01) 0.05
Multivessel disease 1.09 (0.78–1.53) 0.62
Proximal left anterior descending lesion 1.46 (1.01–2.12) 0.04 1.62 (1.06–2.47) 0.03
Ostial lesion 0.99 (0.58–1.70) 0.97 0.87 (0.50–1.52)† 0.63
Total occlusion 0.79 (0.35–1.82) 0.59
Calcification 1.26 (0.86–1.86) 0.24 1.11 (0.71–1.73)† 0.66
Length $10 mm 1.61 (1.05–2.47) 0.03 1.62 (1.04–2.51) 0.03
Reference vessel diameter* 1.10 (0.76–1.61) 0.61
Preprocedural minimum luminal diameter* 1.02 (0.54–1.93) 0.95
Preprocedural percent diameter stenosis* 1.00 (0.99–1.01) 0.95
Postprocedural minimum luminal diameter* 1.03 (0.61–1.73) 0.91
Postprocedural percent diameter stenosis* 1.02 (0.99–1.04) 0.14 1.02 (0.99–1.04)† 0.27
*Per one-unit increase in the covariate value. †Variables “forced” into multivariate model.
1886 Cantor et al. JACC Vol. 37, No. 7, 2001
Stent-Like Outcomes With Balloon Angioplasty June 1, 2001:1883–90
plasty. Repeat revascularization rates for this strategy were
assumed to be 14% (2,13,14). In the second strategy
(provisional stenting guided by baseline characteristics and
angiographic results), patients would not undergo stenting if
they had a stent-like angiographic result (residual diameter
stenosis #30%, no dissection) and none of the three
predictors of repeat revascularization (female gender, lesion
length $10 mm or proximal LAD lesion). With this
strategy, 8% of patients would be treated with angioplasty
alone and the remainder of patients would receive stents.
The repeat revascularization rate of 14% in this low risk
subgroup is equal to the repeat revascularization rate after
stent implantation (2,13,14). In the third strategy (provi-
sional stenting guided by angiography only), patients who
achieve a stent-like angiographic result with angioplasty
(18% of patients) were not stented. The repeat revascular-
ization rate for patients treated with angioplasty alone in
this strategy is 20%.
On the basis of the modalities of repeat revascularization
observed in our database, we assumed that percutaneous
revascularization would be used in 75% of repeat interven-
tions, bypass surgery in 17% and both in the remaining 8%.
Patients undergoing repeat percutaneous intervention were
assumed to receive a stent if they were treated initially with
angioplasty only, and vice versa.
Table 4 summarizes the clinical outcomes and costs of the
three strategies. In the elective stenting strategy and the
provisional stenting strategy guided by both baseline char-
acteristics and angiographic results, the expected rate of
repeat revascularization is 14%. The expected rate of repeat
revascularization in the provisional stenting strategy guided
by angiographic criteria alone is 1% higher (15%). Both
provisional stenting strategies result in cost savings, with the
lowest cost in the angiographic-guided provisional stenting
strategy. In this least-cost strategy, the savings from using
fewer stents are minimally offset by the costs associated with
the slightly higher repeat revascularization rate. Although
expected costs per patient do not vary greatly among these
strategies, when considered from a health system perspec-
tive, substantial savings could be achieved by following the
provisional stenting strategies.
To assess the sensitivity of results to model assumptions,
we varied key parameters in the model. The cost savings
associated with provisional stenting guided by both baseline
characteristics and angiography declined with the cost of
stents. If stent costs fell to 50% of the baseline value,
aggregate savings would fall to $37 million. However, the
provisional strategy did not become more expensive than
elective stenting until stent costs fell to ,$200. The cost
savings were also sensitive to the rate of repeat revascular-
ization after stenting. For example, if the repeat revascular-
ization rate were 10% rather than 14%, the aggregate
savings would fall to $53 million. The cost savings with a
repeat revascularization rate of 5% after stenting are more
modest at $23 million.
The provisional stenting strategy guided by angiography
alone became more expensive than the more selective
provisional stenting strategy with very small changes in stent
costs and repeat revascularization rates. This sensitivity is
Figure 2. Stratification of risk for repeat revascularization at six months for
patients with optimal (stent-like) angiographic results. Using three baseline
characteristics (gender, lesion length and lesion location), patients are
classified as low risk (repeat revascularization rate of 14%) or high risk
(repeat revascularization rate of 25%). DS 5 diameter stenosis; LAD 5 left
anterior descending coronary artery.
Table 4. Six-Month Clinical Outcomes and Costs for Stenting Strategies
Strategy
Cases
Stented
Expected Repeat
Revascularization
Rate (%)*
Overall
Six-Month Cost
Overall Savings
in U.S./Year†
Elective stenting for all patients 100% 14% $16,396 —
Provisional stenting strategies
Angiographic‡ and clinical§ criteria 92% 14% $16,240 $78 million
Angiographic‡ criteria only 82% 15% $16,231 $83 million
*Repeat revascularization rate after stenting assumed to be 14% for all strategies. †Assumes 500,000 stent cases performed per
year in the U.S. ‡Stent if final diameter stenosis .30% or dissection present. §Stent if female, lesion length $10 mm or lesion
in proximal left anterior descending artery.
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due to the relatively high rate of repeat revascularization
among the 18% of patients not initially stented. This
strategy is therefore both clinically and economically unat-
tractive.
DISCUSSION
Major findings. We have shown that the combination of
angiographic residual diameter stenosis and baseline patient
and lesion characteristics can be used to identify a subset of
patients at low risk for repeat revascularization after stan-
dard angioplasty. Combining angiographic results with
baseline characteristics improves the sensitivity for predict-
ing repeat revascularization compared with reliance upon
angiographic results alone. The rate of repeat revasculariza-
tion in the low risk cohort is similar to that observed with
stent implantation (2,13,14). Although only a small propor-
tion of patients undergoing angioplasty fall into this low risk
category, the cost savings achieved by avoiding unnecessary
stent use in this subgroup are substantial.
Provisional stenting. Randomized trials have shown lower
restenosis and repeat revascularization rates with stenting
than with balloon angioplasty (1,2). On the basis of these
encouraging results, many institutions advocate and practice
universal stenting (15). When restenosis does occur within
stents, however, it is often difficult to manage and refractory
to conventional percutaneous interventions (16–18). Previ-
ous attempts to identify patients with favorable outcomes
after standard angioplasty have focused on the postproce-
dural residual diameter stenosis. The BElgium-
NEtherlands Stent (BENESTENT) trial investigators
showed that patients with stent-like angiographic results,
defined as a residual stenosis #30% with no major dissec-
tion, had clinical and angiographic outcomes similar to
those of patients who underwent stenting (19). This finding
has been validated in other stent trials (20,21) and angio-
plasty registries (22,23).
The Optimum Percutaneous transluminal coronary an-
gioplasty compared with roUtine Stent strategy (OPUS)
study was the first randomized trial of provisional stenting
based on angiographic results (24). A total of 479 patients
were randomized to a strategy of elective stent implantation
or initial balloon angioplasty, with provisional stenting for a
residual stenosis $20% by visual assessment (or $30% by
QCA), significant dissection or threatened closure. At six
months, patients randomized to elective stenting had lower
rates of TVR. The use of visual estimation rather than QCA
may account in part for the discrepancy with previous
studies. However, these results are consistent with our
observation that angiographic criteria alone may be inade-
quate to identify patients at low risk for restenosis and
repeat intervention.
Two small trials have shown the feasibility of a provi-
sional stenting strategy guided by repeating angiography 20
to 30 min after balloon angioplasty to assess for early recoil
(25,26). The use of intravascular ultrasound and physiologic
measurements, including coronary and fractional flow re-
serve, may help discriminate which patients will have
favorable clinical outcomes with balloon angioplasty alone
(27–31). However, these modalities prolong procedure
times and carry additional costs. In contrast, the use of
angiographic results and baseline characteristics to guide
stent use is simple and inexpensive.
Our analysis focused primarily on the incidence of repeat
revascularization. A meta-analysis of trials comparing stent-
ing and balloon angioplasty demonstrated that the primary
clinical benefit of stent implantation is a reduction in the
need for repeat revascularization, with no difference in the
incidence of death or MI (32). The other potential advan-
tage of stent implantation is a reduction in the incidence of
abrupt occlusion. In this study, the rates of death, MI and
repeat revascularization within 48 h after intervention for
patients with optimal angiographic results were low (0%, 2%
and 3% respectively) and similar to the rates reported after
stent implantation in a recent large randomized trial (33).
Nevertheless, we cannot exclude the possibility that early
ischemic complications may occur more often with provi-
sional stenting.
Glycoprotein IIb/IIIa inhibitors were used in 41% of the
cases in this study. In the Evaluation of Platelet IIb/IIIa
Inhibitor for Stenting (EPISTENT) study, the combina-
tion of stenting and glycoprotein IIb/IIIa inhibitors was
associated with significantly lower rates of death, MI and
TVR at one year than either therapy alone (34). However,
stents were used in the angioplasty group only for reduced
coronary flow, long dissections or a residual diameter
stenosis .70% and were implanted in only 19% of patients.
The outcomes of the EPISTENT angioplasty group were
likely related in part to the patients with suboptimal
angiographic results who did not receive stents. In the
provisional stenting described in this study, stents were used
in .90% of patients and only the lowest risk patients were
treated with angioplasty alone. However, a direct compar-
ison of this provisional stenting strategy with routine stent-
ing in the background of intravenous glycoprotein IIb/IIIa
inhibition is needed to validate these findings.
Cost implications. Although ,10% of all eligible patients
fall into the low risk category, our cost analysis shows a
potentially substantial cost savings of $78 million on a
national basis achieved by avoiding unnecessary stenting in
this small subgroup. Prior cost analyses of stenting strategies
have shown significantly higher in-hospital costs with stent-
ing, but the difference in costs is offset somewhat by the
lower rate of repeat revascularization procedures (3,35–37).
Our findings suggest that in a select group of patients,
treatment with balloon angioplasty alone is associated with
repeat revascularization rates similar to those seen with
stenting, and the initial cost savings achieved by avoiding
stent use are maintained over six months. In addition to the
economic benefits, these strategies lower the rates of in-
stent restenosis.
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Predictors of repeat revascularization. The multivariate
model in this analysis identified three independent predic-
tors of repeat revascularization among patients with optimal
angiographic results: female gender, proximal LAD lesion
and lesion length $10 mm. Absence of prior MI was also
associated with the need for repeat revascularization, al-
though with borderline statistical significance. Numerous
prior studies have identified predictors of angiographic
restenosis. Longer lesion length (38–40), proximal LAD
lesion location (38,41–43) and the absence of previous MI
(44) have been shown to be associated with higher rates of
angiographic restenosis in previous studies. With respect to
gender differences, early studies reported higher restenosis
rates in men (42,44,45). However, subsequent studies
showed no difference between genders, and it has been
postulated that the difference observed in earlier studies may
have been related to inadequate lumen enlargement in larger
vessels attributable to the limitations of older angioplasty
equipment (46). Women have higher rates of acute closure
after angioplasty, which may account for the more frequent
need for repeat percutaneous intervention during the initial
hospitalization (47,48). Diabetes has been shown to be a
significant predictor of restenosis in some (39,43), but not
all (40,42,49), prior studies. In this analysis, the slightly
higher rate of repeat revascularization in patients with
diabetes was not statistically significant (21.8% vs. 19.6%;
p 5 0.5). It is possible that patients with diabetes have
higher rates of asymptomatic restenosis that may not lead to
repeat revascularization. Alternatively, diabetes may not be
an important risk factor for restenosis when optimal angio-
graphic results are achieved. Higher restenosis rates have
also been reported for total occlusions, ostial lesions and
multivessel intervention (50). In this study, relatively few
patients with optimal angiographic results had these char-
acteristics (5%, 13% and 7% respectively), and the analysis
was therefore insufficient to evaluate the association be-
tween these factors and repeat revascularization rates.
Study limitations. The patients in this analysis were en-
rolled in clinical trials with strict inclusion and exclusion
criteria, and complex lesions may therefore be underrepre-
sented compared with clinical practice. Furthermore, saphe-
nous vein graft interventions were excluded from the anal-
ysis. No direct comparison with coronary stenting was
undertaken in this study. The low rate of repeat revascular-
ization after standard balloon angioplasty in the low risk
cohort compares favorably with the rates seen after stenting
in prior studies. However, our findings require further
validation, including prospective comparison with patients
undergoing stenting. It is possible that patients with favor-
able clinical and angiographic characteristics who undergo
stenting have significantly lower rates of repeat revascular-
ization than the overall rate used for this analysis.
Conclusions. Optimal or stent-like angiographic results
(defined as residual diameter stenosis #30% and no dissec-
tion) are achieved in about 20% of patients and are associ-
ated with lower rates of repeat revascularization and MI
than cases with non-SLRs. Further stratification of these
cases based on gender, lesion length and lesion location
allows identification of a group of patients at low risk for
repeat revascularization. Men with stent-like angiographic
results after angioplasty in short lesions located outside the
proximal LAD are unlikely to require stent implantation
and may be best managed with angioplasty alone. A
provisional stent strategy based on the use of final angio-
graphic results and preprocedural characteristics can provide
substantial cost savings, with clinical outcomes equivalent to
a strategy of universal stenting.
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